Alivus Life Sciences Ltd.
ALIVUS.NS
Get informed when a big investor buys or sells
+ FollowMarket Cap$153.54B
Close$
$734.07
41.3% downside
Current Fair Value
41.3% downsideOvervalued by 41.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $153.54 Billion |
|---|---|
| Enterprise Value | $154.08 Billion |
| Dividend Yield | $5.00 (0.40%) |
| Earnings per Share | $45.99 |
| Beta | 0.05 |
| Outstanding Shares | 122,739,448 |
Return
| Return on Equity | 18.10% |
|---|---|
| Return on Assets | 15.14% |
| Return on Invested Capital | 22.89% |
Valuation & Multiples
| P/E Ratio | 25.46 |
|---|---|
| PEG | 80.29 |
| Price to Sales | 5.93 |
| Price to Book Ratio | 4.61 |
| Enterprise Value to Revenue | 5.95 |
| Enterprise Value to EBIT | 19.37 |
| Enterprise Value to Net Income | 25 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$12.10
Average shareholder expectationRevenue Estimate
$6.80 B
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$12.50
Average shareholder expectationRevenue Estimate
$6.42 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Alivus Life Sciences Limited
2,272 employees
CEO: Yasir Yusufali Rawjee Alivus Life Sciences Limited, established in Mumbai, India, in 2001, is a pharmaceutical company that handles the full spectrum of active pharmaceutical ingredient (API) operations, from initial development and meticulous production to w...